Transchem Ltd Stock Price Today (NSE: TRANSCHEM)
Fundamental Score
Transchem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Transchem Ltd share price today is ₹162.65, up +1.96% on NSE/BSE as of 30 March 2026. Transchem Ltd (TRANSCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹122.99 (Cr). The 52-week high for TRANSCHEM share price is ₹194.25 and the 52-week low is ₹31.10. At a P/E ratio of 32.45x, TRANSCHEM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.75% and a debt-to-equity ratio of 0.00.
Transchem Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Transchem Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Transchem Share Price: A Financial Risk Analysis
The pharmaceutical industry, often lauded for its inelastic demand driven by healthcare necessities, faces increasing scrutiny regarding research and development spending versus actual therapeutic innovation. This analysis examines the financial stability of Transchem Ltd, focusing on publicly available data surrounding the Transchem share price, which currently stands at ₹164.449997. This is part of a comprehensive, 80-parameter fundamental audit verified by Sweta Mishra, ensuring a rigorous and objective assessment.
Transchem's Price-to-Earnings (PE) ratio of 32.45 suggests the market holds relatively high expectations for future earnings growth. Compared to some sector peers, this valuation indicates investors are paying a premium. We can also contrast Transchem Ltd with peers such as
Mankind Pharma Ltd. While quantifiable metrics provide insights, subjective factors like management quality play a crucial role. Mankind Pharma Ltd., for instance, is often perceived to have a more seasoned management team with a proven track record of successful product launches and strategic acquisitions. A deeper qualitative analysis would be needed to assess if Transchem's leadership inspires similar confidence.Return on Capital Employed (ROCE) is a key metric for evaluating profitability and capital efficiency. Transchem’s ROCE of 9.11% indicates the company is generating ₹9.11 of profit for every ₹100 of capital employed. This level of ROCE is important in evaluating Transchem's economic moat. A higher ROCE typically suggests a stronger competitive advantage, allowing the company to reinvest earnings at attractive rates, further strengthening its market position. While 9.11% is positive, a significantly higher ROCE would suggest a more defensible and wider economic moat. Further investigation is required to determine if this ROCE is sustainable and reflective of true long-term performance.
This analysis is purely observational and based on publicly available data. It does not constitute financial advice, and no buy or sell recommendations are being made. Investors should conduct their own independent research and consult with a qualified financial advisor before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Transchem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TRANSCHEM across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent EPS Growth (68.07% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (68.07% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (56.45%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (6.75%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.11%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-52.78%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 0.04%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Transchem Ltd Financial Statements
Comprehensive financial data for Transchem Ltd including income statement, balance sheet and cash flow
About TRANSCHEM (Transchem Ltd)
Transchem Ltd is a dynamic, research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. We are focused on address...ing unmet medical needs in key therapeutic areas such as oncology, immunology, and central nervous system disorders. Our state-of-the-art research facilities and collaborative partnerships with leading academic institutions and biotech firms enable us to push the boundaries of pharmaceutical science. We pride ourselves on a commitment to scientific excellence, ethical practices, and patient-centricity, striving to improve the lives of individuals worldwide through the power of transformative medicines. Transchem's pipeline encompasses a diverse portfolio of novel drug candidates, from early-stage preclinical assets to late-stage clinical programs. At Transchem, we are driven by a passionate team of scientists, clinicians, and business professionals with a shared vision of creating breakthrough pharmaceuticals. Our core values are rooted in integrity, innovation, and collaboration, fostering a culture where creativity thrives and every individual is empowered to make a meaningful contribution. We maintain a strong focus on precision medicine, leveraging advanced technologies like genomics and bioinformatics to tailor treatments to individual patient profiles. This approach allows us to maximize therapeutic efficacy and minimize adverse effects. Furthermore, we are committed to sustainable and responsible practices throughout our operations, minimizing our environmental impact and supporting the communities we serve. TRANSCHEM actively seeks strategic alliances and licensing opportunities to expand our product portfolio and accelerate the delivery of novel therapies to patients. Our experienced business development team is dedicated to identifying and evaluating promising drug candidates and technologies that align with our strategic priorities. We are committed to building long-term, mutually beneficial partnerships with other pharmaceutical companies, biotech firms, and academic institutions. By combining our expertise and resources, we can collectively address the most pressing healthcare challenges and improve patient outcomes globally. TRANSCHEM is poised to emerge as a leader in the pharmaceutical industry, driven by our unwavering commitment to innovation, patient care, and global health.
Company Details
Key Leadership
Latest News
TRANSCHEM Share Price: Frequently Asked Questions
What is the current share price of Transchem Ltd (TRANSCHEM)?
As of 30 Mar 2026, 12:03 pm IST, Transchem Ltd share price is ₹162.65. The TRANSCHEM stock has a market capitalisation of ₹122.99 (Cr) on NSE/BSE.
Is TRANSCHEM share price Overvalued or Undervalued?
TRANSCHEM share price is currently trading at a P/E ratio of 32.45x, compared to the industry average of 31.77x. Based on this relative valuation, the Transchem Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of TRANSCHEM share price?
The 52-week high of TRANSCHEM share price is ₹194.25 and the 52-week low is ₹31.10. These values are updated daily from NSE/BSE price data.
What factors affect the Transchem Ltd share price?
Key factors influencing TRANSCHEM share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Transchem Ltd a good stock for long-term investment?
Transchem Ltd shows a 5-year Profit Growth of 68.07% and an ROE of 6.75%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in TRANSCHEM shares.
How does Transchem Ltd compare with its industry peers?
Transchem Ltd competes with major peers in the Pharmaceuticals. Investors should compare TRANSCHEM share price P/E of 32.45x and ROE of 6.75% against the industry averages to determine competitive standing.
What is the P/E ratio of TRANSCHEM and what does it mean?
TRANSCHEM share price has a P/E ratio of 32.45x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is TRANSCHEM performing according to Bull Run's analysis?
TRANSCHEM has a Bull Run fundamental score of 36.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does TRANSCHEM belong to?
TRANSCHEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Transchem Ltd share price.
What is Return on Equity (ROE) and why is it important for TRANSCHEM?
TRANSCHEM has an ROE of 6.75%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Transchem Ltd generates profits from shareholders capital.
How is TRANSCHEM debt-to-equity ratio and what does it indicate?
TRANSCHEM has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is TRANSCHEM dividend yield and is it a good dividend stock?
TRANSCHEM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Transchem Ltd shares.
How has TRANSCHEM share price grown over the past 5 years?
TRANSCHEM has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth 68.07%, and EPS Growth 68.07%.
What is the promoter holding in TRANSCHEM and why does it matter?
Promoters hold 56.45% of TRANSCHEM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Transchem Ltd.
What is TRANSCHEM market capitalisation category?
TRANSCHEM has a market capitalisation of ₹123 crores, placing it in the Small-cap category.
How volatile is TRANSCHEM stock?
TRANSCHEM has a beta of N/A. A beta > 1 suggests the Transchem Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is TRANSCHEM operating profit margin trend?
TRANSCHEM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is TRANSCHEM quarterly performance?
Recent quarterly performance shows Transchem Ltd YoY Sales Growth of N/A% and YoY Profit Growth of -52.78%.
What is the institutional holding pattern in TRANSCHEM?
TRANSCHEM has FII holding of 0.03% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the Transchem Ltd stock.